Clinical trials: Diuretics
Healthy Participants
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy Participants
The purpose of this study is to evaluate the safety, tolerability, drug levels, and drug effects of BMS-986308 compared to placebo in healthy participants.
- Trial name
- NCT04763226
- Testing
- BMS-986308, Furosemide
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Heart Failure
A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure
This study assessed the interaction between single and multiple doses of aliskiren (150 mg and 300 mg) and furosemide (60 mg) in patients with heart failure.
- Trial name
- NCT01125514
- Testing
- Aliskiren 150 mg, Furosemide 60 mg, Aliskiren 300 mg
- Where
- 2 sites in Germany, Lithuania
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
Ascites, Liver Cirrhosis
Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver
Primary: To evaluate the efficacy of satavaptan in the absence of concomitant diuretic drugs in reducing the recurrence of ascites.
- Trial name
- SPARe-2 (NCT00366795)
- Testing
- Satavaptan
- Where
- 21 sites in United States, Argentina and 19 more
- Volunteers
- 241 people
- Sponsor
- Sanofi
Heart Failure, Edema
Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure
The primary objective of this study is to learn whether a morning dose of extended-release torsemide enhances renal sodium excretion after lunch (4-8 hours after dosing) compared to immediate-release torsemide.
- Conditions
- Heart Failure, Edema, Pulmonary Congestion, Fluid Overload
- Trial name
- NEXT-HF (NCT06995144)
- Testing
- Extended Release Torsemide Tablets, Immedate Release Torsemide Tablets
- Where
- United States
- Sponsor
- Sarfez Pharmaceuticals, Inc.
Congestive Heart Failure
Study to Evaluate Cardiac Hemodynamics and Safety of SLV320 in Subjects With Congestive Heart Failure
The study is a randomized, placebo controlled, multi-center, single dose study to evaluate cardiac hemodynamics and safety of iv SLV320 in 110 subjects with congestive heart failure requiring diuretic treatment.
- Trial name
- NCT00160134
- Testing
- SLV320
- Where
- Germany
- Sponsor
- Solvay Pharmaceuticals
AKI - Acute Kidney Injury, Cardiac Surgery
Urine Output Response to Fluid and Diuretic Therapy in Cardiac ICU Patients Monitored With FIZE kUO®
This prospective observational study evaluates the real-time urine output response to fluid therapy and diuretics in cardiothoracic intensive care unit (CTICU) patients monitored with the FIZE kUO® device.
- Conditions
- AKI - Acute Kidney Injury, Cardiac Surgery, Fluid Therapy, Hemodynamic Instability
- Trial name
- NCT07022314
- Testing
- FIZE kUO®
- Where
- Israel
- Volunteers
- 45 people
- Sponsor
- FIZE Medical ltd
Hypertension
DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension
This is a research study of a new experimental drug called darusentan. Darusentan is not currently approved by the U.S. Food and Drug Administration (FDA) for use in the United States, which means that a doctor cannot prescribe…
- Trial name
- NCT00330369
- Testing
- Darusentan
- Where
- 115 sites in United States, Argentina and 9 more
- Volunteers
- 352 people
- Sponsor
- Gilead Sciences
Acute Decompensated Heart Failure
DORAYA-HF Early Feasibility Study
The study objective is to evaluate the feasibility of the Doraya Catheter and measure clinical performance and safety endpoints, in ADHF patients deemed to have insufficient diuretic response.
- Trial name
- NCT05206422
- Testing
- Doraya Catheter
- Where
- 14 sites in United States
- Volunteers
- 21 people
- Sponsor
- Revamp Medical Inc.
Diabetes Mellitus
Examining the Effect of Different Diuretics on Fluid Retention in Diabetics Treated With Rosiglitazone.
Study examining the effect of different diuretics on fluid retention in diabetics treated with rosiglitazone.
- Trial name
- NCT00306696
- Testing
- Rosiglitazone, spironolactone, hydrochlorothiazide
- Where
- 46 sites in Belgium, Canada and 12 more
- Volunteers
- 388 people
- Sponsor
- GlaxoSmithKline
Heart Failure (for Example, Fluid Overload), Heart Failure
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
The REVERSE-HF study is a randomized controlled trial to evaluate clinical outcomes of adjustable ultrafiltration with the Aquadex System as compared to adjustable IV loop diuretics in patients with worsening heart failure (HF)…
- Conditions
- Heart Failure (for Example, Fluid Overload), Heart Failure, Fluid Overload
- Trial name
- REVERSE-HF (NCT05318105)
- Testing
- Aquadex Smartflow® System, IV Loop Diuretics
- Where
- 15 sites in United States
- Volunteers
- 167 people
- Sponsor
- Nuwellis, Inc.
Heart Failure
Remote Monitoring of Ambulatory Intravenous Diuretics in Heart Failure
This study will aim to collect proof of concept data to inform the study design of a larger paired comparison study to establish key research questions about the Heartfelt device.
- Trial name
- MONITORED-HF (NCT05193084)
- Testing
- Heartfelt Device, Connected weighing scales
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- Heartfelt Technologies
Nocturia
Efficacy Study of VA106483 in Males With Nocturia.
To investigate the effect of VA106483 on nocturia related clinical outcomes compared to placebo.
- Trial name
- NCT01038843
- Testing
- VA106483
- Where
- 19 sites in United States
- Volunteers
- 152 people
- Sponsor
- Vantia Ltd
Renal Edema, Nephrogenic Edema
A Study of JMKX003142 Tablet to Treat Renal Edema
To evaluate the efficacy, safety, and of JMKX003142 administered randomly, double-blind, placebo-controlled study in Chinese renal edema patients with inadequate response to conventional diuretic therapy.
- Trial name
- NCT07841093
- Testing
- JMKX003142 Tablets
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Jemincare
Heart Failure, Congestive
PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function
The study is being conducted to examine whether KW-3902IV will result in greater improvement in signs and symptoms of heart failure, with less treatment failure than standard therapy, when it is added to IV loop diuretics in…
- Trial name
- NCT00354458
- Testing
- rolofylline
- Volunteers
- 1,102 people
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Nocturia, Benign Prostatic Hypertrophy (BPH)
Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH)
The purpose of this study is to establish the dose response relationship of VA106483 and nocturnal urine volumes in a population of elderly male subjects with Benign Prostatic Hypertrophy (BPH) who are likely to present with…
- Trial name
- NCT01330927
- Testing
- VA106483
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Vantia Ltd
Hypertension
A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.
Valsartan, an orally active angiotensin II receptor blocker, is registered in most countries worldwide for the treatment of hypertension. In China the usual recommended starting and maintenance dose is 80 mg o.d.
- Trial name
- NCT00250562
- Testing
- valsartan plus hydrochlorothiazide
- Where
- United States
- Volunteers
- 1,171 people, healthy volunteers welcome
- Sponsor
- Novartis
Cardiac Edema
A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)
To investigate the pharmacokinetics, pharmacodynamics (urine volume and fluid intake), efficacy(body weight, pulmonary congestion and other congestions including cardiothoracic ratio) and safety of 7-day repeated oral…
- Trial name
- NCT00525265
- Testing
- OPC-41061(Tolvaptan)
- Where
- 2 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Heart Failure, Cardiac Failure
Study of Heart Failure Hospitalizations After Aquapheresis Therapy Compared to Intravenous (IV) Diuretic Treatment
The purpose of the research is to determine if patients have fewer Heart Failure (HF) events after receiving Aquapheresis (AQ) therapy compared to intravenous (IV) diuretics up to 90 days of discharge from the hospital.
- Conditions
- Heart Failure, Cardiac Failure, Acute Decompensated Heart Failure (ADHF)
- Trial name
- AVOID-HF (NCT01474200)
- Testing
- Isolated veno-venous ultrafiltration (AQ), IV Loop Diuretics (LD)
- Where
- 38 sites in United States
- Volunteers
- 224 people
- Sponsor
- Nuwellis, Inc.
Bioavailability Heathy Volunteers
A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects
This study will examine comparative bioavailability of single dose of a fixed dose combination (FDC) of extended release Torsemide and Spironolactone given with or without food in healthy adult subjects.
- Trial name
- NCT07043634
- Testing
- FDC (24 mg ER torsemide and 30 mg Spironolactone) without food, FDC (24 mg ER torsemide and 30 mg Spironolactone) with food
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sarfez Pharmaceuticals, Inc.
Heart Failure, Congestive
Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV Therapy
To evaluate the effect of KW-3902IV, in addition to standard therapy, on the proportion of worsening heart failure and worsening renal function, and on the proportion of deaths or rehospitalizations for heart failure or worsening…
- Trial name
- REACH UP (NCT00443690)
- Testing
- rolofylline
- Volunteers
- 480 people
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)